California Public Employees Retirement System Cuts Stock Position in Bristol Myers Squibb Company $BMY

California Public Employees Retirement System trimmed its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 8.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,645,956 shares of the biopharmaceutical company’s stock after selling 538,304 shares during the period. California Public Employees Retirement System owned 0.28% of Bristol Myers Squibb worth $254,633,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. CVA Family Office LLC raised its position in shares of Bristol Myers Squibb by 2.6% during the 3rd quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 223 shares during the last quarter. MSH Capital Advisors LLC increased its stake in Bristol Myers Squibb by 2.9% during the 3rd quarter. MSH Capital Advisors LLC now owns 8,034 shares of the biopharmaceutical company’s stock worth $362,000 after buying an additional 223 shares in the last quarter. Bell & Brown Wealth Advisors LLC increased its stake in Bristol Myers Squibb by 0.5% during the 3rd quarter. Bell & Brown Wealth Advisors LLC now owns 42,691 shares of the biopharmaceutical company’s stock worth $1,925,000 after buying an additional 224 shares in the last quarter. Addison Advisors LLC raised its holdings in shares of Bristol Myers Squibb by 6.2% during the third quarter. Addison Advisors LLC now owns 3,972 shares of the biopharmaceutical company’s stock valued at $179,000 after acquiring an additional 232 shares during the last quarter. Finally, Mccarter Private Wealth Services LLC lifted its position in shares of Bristol Myers Squibb by 5.0% in the third quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock valued at $222,000 after acquiring an additional 235 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $59.02 on Monday. The firm has a 50-day simple moving average of $58.24 and a two-hundred day simple moving average of $51.46. The stock has a market cap of $120.18 billion, a PE ratio of 17.11, a P/E/G ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter in the prior year, the company posted $1.67 earnings per share. The business’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Leerink Partners increased their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Finally, HSBC restated a “hold” rating and set a $53.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Nine investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus target price of $61.00.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.